COGENTIS THERAPEUTICS INC
Baltimore, MD · Biotech · Private
CT526, a synthetic cell-permeable peptide inhibitor of CDK5-p25 for ALS treatment
cogentistherapeutics.com →- Grants
- $5.9M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of CDK5-p25 modulator to treat Alzheimer's Disease and Frontotemporal Dementia | $497,121 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of CDK5-p25 modulator to treat Alzheimer's Disease and Frontotemporal Dementia | $733,446 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of CDK5-p25 modulator to treat Alzheimer's Disease and Frontotemporal Dementia | $236,325 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis | $1,183,364 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis | $2,210,678 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis | $1,027,314 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1413 | Abcombi Biosciences Inc | — | — |
| 1414 | DeNovoTherapies LLC | — | — |
| 1415 | Op-T-Mune, Inc | — | — |
| 1416 | COGENTIS THERAPEUTICS INC | — | — |
| 1417 | Omega Biosystems Incorporated | — | — |
| 1418 | Omm Scientific, Inc | — | — |
| 1419 | EVODENOVO INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.